A prospective single-arm, open-label, multicenter phase 2 trial evaluated the efficacy and safety of combined BRAF/mitogen-activated protein kinase(MEK) inhibition (using encorafenib and binimetinib) in patients with relapsed/refractory multiple myeloma (RRMM) carrying the BRAFV600E mutation (NCT02834364). Here, BRAF is linked to plasma cell myeloma.